Extraskeletal Osteochondroma of the Heel A Case Report

Image

Osteochondroma is the most common benign bone tumor and usually occurs in the metaphyseal region of the long bones around the knee. This is acartilage-capped bony tumor, which out growths on the surface of the bone. Extra skeletal osteochondroma is a variant of extra skeletal chondromas that are uncommon soft-tissue cartilaginous tumors. This report describes the case of a 56-year-old woman with an extraskeletal osteochondroma of the heel.

Osteochondroma are present approximately 10–15% of all bone tumors [1]. Usually represent as cartilage capped tumor around the knee such as proximal tibia and distal femur. Extra skeletal osteochondromas also seen rarely. Peak occurrence is during the 3rd and 6th decades. Extra skeletal osteochondromas are often benign tumors and local excision is known as the Standard treatment if tumor is symptomatic. With only few data on literature, treatment choice may depends on the risk of malignant transformation. This article presents a case of an extra skeletal osteochondroma arising of heel.

 

This osteolytic lesion could be contributed to the increased osteoclastic bone resorption. So far, the molecule mechanisms of the interaction between the breast cancer cell and bone marrow microenvironment have been explored by many researchers, and in animal models, some agents have also demonstrated having therapeutic effect for bone metastasis in breast cancer by inhibiting the responsible mechanisms. However, breast cancer bone metastasis is a complex process in which each stage are affecting each other, there is still no specific pharmacologic agent available for preventing or reversing bone metastasis in breast cancer patients. Thus, further efforts should be made on how to build the models of bone metastasis which can be used to incorporate all of those affecting factors mentioned above, and how can all the complex interactions in the bone microenvironment be blocked to treat breast cancer bone metastasis. With the development of animal models, molecular biology and gene chip technology, we believe that the molecule mechanism of bone metastasis will be further understood, and then the new targeting drug will be found to cure the bone metastasis in breast cancer.

Osteochondromas, is the most common benign tumor of bone and rarely seen extra skeletally. It has been reported that they have low risk of malignant degeneration. We think, no surgical treatment is needed as long as these osteochondromas does not have risk factors for malignant transformation and stay asymptomatically, otherwise surgical excision should be the choice of treatment.

Media Contact:
Stella

Managing Editor

Journal of Orthopedic Oncology.
Email: orthooncol@emedscience.org

What’s App: +1-947-333-4405